Chemists at Scripps Research in La Jolla say they have pulled off a bold molecular renovation of fentanyl, carving out its chemical core and dropping in a compact substitute that keeps the powerful pain relief in animals while sharply dialing down the drug's worst traits. In lab tests and mouse studies, the experimental compound preserved strong analgesia yet showed markedly less respiratory depression and weaker signs of addiction risk.
The team did not simply polish fentanyl's edges. They replaced its central ring with a tight 2-azaspiro[3.3]heptane scaffold, a topological overhaul that changed both potency and how the molecule behaves in the body. So far, the work lives entirely in laboratory assays and mouse models, with early data described in a peer-reviewed chemistry letter and flagged by the institute as a proof-of-concept path toward opioids with a wider safety margin. Researchers stress that human trials are a distant prospect.
Local coverage in the San Diego Business Journal on March 20, 2026 pushed the study beyond specialist circles and checked in with the Janda laboratory about the chemistry and what comes next. The piece identified Arran Stewart as the paper's first author and reported that the project was backed by the Shadek Family Foundation. Scripps researchers told the outlet they plan to treat the new spirocore as a modular blueprint, tuning signaling, exposure and potency to generate potential drug candidates or even protective vaccines.
"What we did was chop off one of the arms," principal investigator Kim D. Janda told the San Diego Business Journal, summing up the core swap behind the redesigned molecule. Stewart told the paper that the group intentionally targeted the molecule's central geometry instead of making the usual small tweaks, a move the lab says produced a surprisingly favorable split between pain relief and respiratory risk in their tests.
How the Chemistry Works
In medicinal-chemistry terms, the move is a classic "scaffold hop": the scientists traded fentanyl's piperidine core for a 2-azaspiro[3.3]heptane bioisostere. That switch preserves the key pharmacophore vectors, the business ends of the molecule that talk to the receptor, while locking in more rigid shape, according to Scripps Research.
The institute reports that the spirocore maintained preference for the μ-opioid receptor yet essentially eliminated recruitment of β-arrestin-2, a signaling pathway often implicated in dangerous opioid side effects. The analogue also showed a short systemic half-life in animals. In the Scripps account, that mix of receptor bias and rapid clearance is tied to the lower respiratory liability. The group is pitching the scaffold as a tunable framework for reshaping opioid signaling and drug disposition without instantly throwing away analgesic punch.
Early Animal Results
In the peer-reviewed letter published in ACS Medicinal Chemistry Letters, the compound posted full antinociceptive responses in standard hot-plate and tail-flick assays, the go-to pain tests in mice, even though it was roughly 100 times less potent than fentanyl by dose. In animals, the analogue acted briefly, with a serum half-life of about 27 minutes.
Respiratory effects told a different story. According to the paper, the modified molecule produced dose-dependent respiratory depression only at much higher doses than fentanyl. The authors argue that the topological swap disconnects potency from exposure, giving chemists concrete levers to boost affinity later while keeping the improved breathing profile that shows up in these early experiments.
Why This Matters
Synthetic opioids such as fentanyl sit at the center of the United States overdose crisis. Provisional federal figures indicate that synthetic opioids were involved in roughly 70,000 drug overdose deaths in 2023, according to the CDC.
If the spiro-based strategy works in people the way it appears to work in mice, it could represent a fundamentally different way to blunt fatal respiratory depression while preserving medical pain control. That is a sizeable "if." Many animal findings fade during optimization and clinical testing, and researchers and public-health observers alike are warning that any real benefit for patients sits far down the road.
Next Steps and IP
The authors say they plan to run extensive structure-activity relationship campaigns to claw back potency while holding on to the friendlier safety profile, and they are also exploring vaccine approaches that would train the immune system to neutralize fentanyl molecules, according to Scripps Research. The institute notes that it routinely evaluates lab discoveries for intellectual-property protection and that this study drew philanthropic funding from the Shadek Family Foundation.
Transforming a lab prototype into an approved medicine would require substantial optimization, detailed toxicity work and multi-phase clinical trials, a process that plays out over many years under the best of circumstances.
For now, the result sits as what chemists like to call a proof of concept, a concrete example that topological redesign can pry apart analgesia and a deadly side effect in animals. It also adds another entry to San Diego's long history in translational chemistry and hands local researchers a tidy list of molecular knobs to turn, even as the road to safer opioids for real patients stays long and uncertain. The Janda lab's message to colleagues and public-health officials is simple enough: if you want different outcomes, do not just police the molecule, change it.
